Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Liabilities: 2020-2024

Historic Total Liabilities for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $329.5 million.

  • Foghorn Therapeutics' Total Liabilities fell 12.49% to $294.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.6 million, marking a year-over-year decrease of 12.49%. This contributed to the annual value of $329.5 million for FY2024, which is 9.25% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Total Liabilities of $329.5 million as of FY2024, which was down 9.25% from $363.1 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Total Liabilities registered a high of $422.9 million during FY2021, and its lowest value of $109.4 million during FY2020.
  • For the 3-year period, Foghorn Therapeutics' Total Liabilities averaged around $365.8 million, with its median value being $363.1 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 286.54% in 2021, then decreased by 10.29% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Total Liabilities (Yearly) stood at $109.4 million in 2020, then spiked by 286.54% to $422.9 million in 2021, then fell by 4.29% to $404.8 million in 2022, then dropped by 10.29% to $363.1 million in 2023, then declined by 9.25% to $329.5 million in 2024.